Dawood Darbar is a Cardiology physician. ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1801 W Taylor St
Chicago, IL 606124795
Telephone
312-996-6480Provider last certified this registry record 4 Jan 2024.
Clinical trials
- ST-segment Elevation as an AF Endophenotype
Sponsor: Vanderbilt University Medical Center
- QT Variability Pre and Post Cardioversion
Sponsor: Vanderbilt University
- Effects Rapid Atrial Pacing Has on the Electrocardiogram (ECG) in Patients With Dual Chamber Pacemakers
Sponsor: Vanderbilt University
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GE HEALTHCAREProgram year20252 payments
- AltaThera Pharmaceuticals LLCProgram year20253 payments
- Medtronic, Inc.Program year20253 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
55.6%Beta blocker30.2%Metoprolol Succinate73%Metoprolol Tartrate18%Carvedilol10%Part D<11 patientsAntiarrhythmic22.2%Flecainide Acetate68%Amiodarone Hcl33%Part D<11 patients+ 1 more class in this area
Blood & clotting
44.4%Factor Xa inhibitor44.4%Eliquis74%Xarelto27%Part D≥28 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
7 NIH research awards on record, funded 2015–2024 per NIH RePORTER. The latest:
- Genotype-guided therapy for atrial fibrillation
University of Illinois at Chicago
FY2024$682,491R01HL148444 - Genotype-guided therapy for atrial fibrillation
University of Illinois at Chicago
FY2023$698,017R01HL148444
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Gregory Y.H. Lip
Medical University of Białystok
Mika Kivimäki
University of Helsinki
Salim Yusuf
Population Health Research Institute
Victoria Delgado
Institute of Molecular Bioimaging and Physiology
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”